Interdepartmental Training in Pharmacological Sciences

药理学科学跨部门培训

• 批准号: 10616678
• 负责人: Lori L. Isom
• 金额: $ 63.66万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10616678
• 关键词: Science; Training; pharmacologic

This new application requests support for the newly re-designed University of Michigan (U-M) Pharmacological Sciences Training Program (PSTP). The goal of the PSTP is to develop a diverse pool of well-trained biomedical scientists who have the technical, operational and professional skills to conduct pharmacological research in an ethically responsible and rigorous manner, and to enter diverse careers in the biomedical research workforce. Annual support for 12 trainees (6-Year 2 and 6-Year 3 Trainees in any one year) is requested throughout the five years of funding. The U-M PSTP is a long-standing collaboration between the Medical School and the College of Pharmacy that provides synergistic, translational education, research training, and career development for pre-doctoral trainees in four degree-granting programs: Pharmacology, Biological Chemistry, Medicinal Chemistry, and Pharmaceutical Sciences. The new, competency-based PSTP curriculum, which includes an experiential program in Real-World Drug Discovery, is designed to provide trainees with a strong foundational understanding of the pharmacological sciences, to provide training in the performance of rigorous and reproducible research, and to provide career development, teamwork, and leadership training, all under the direction of well-trained and dedicated faculty mentors. An extensive and successful alumni base provides career mentorship, networking, and future employment opportunities. PSTP mentors encourage trainees to think broadly about research problems in human disease while focusing their thesis research on a critical, unmet gap in knowledge using rigorous experimental design and methods. This re-designed strong, interdisciplinary, yet individualized, training in the pharmacological sciences will give trainees a distinct advantage in that they will be rapidly employable and well positioned to contribute to the NIH mission to discover new medicines. The development of novel and effective therapeutic agents is a critical, on-going global need that requires rigorously trained, innovative team players to solve critical problems in health care. It is essential that the US continue to produce doctoral-level scientists from diverse backgrounds with broad training in pharmacological sciences and experimental therapeutics who understand basic science and translational medicine. U-M is a premiere institution in research and training of graduate students in the biomedical sciences on a global scale. Although U-M has individual graduate programs in the Departments associated with this training program, the PSTP is the only program at U-M that draws upon the expertise of faculty, alumni, the Michigan Drug Discovery Institute, and the enthusiasm of students across these units to fertilize interdisciplinary education, collaborative research, career development, and team-based approaches to innovation and translation in target discovery and development of experimental therapeutics.

此新应用程序请求支持新设计的密歇根大学 (U-M) 药理学 科学培训计划（PSTP）。 PSTP 的目标是培养多样化的训练有素的生物医学人才库 具有进行药理学研究的技术、操作和专业技能的科学家 以道德负责和严谨的态度，进入生物医学研究的多元化职业 劳动力。请求每年为 12 名学员提供支持（任何一年中 6 个第 2 年学员和 6 个第 3 年学员） 整个资助的五年。密歇根大学 PSTP 是医学院之间的长期合作 药学院提供协同、转化教育、研究培训和职业 四个学位授予项目的博士前培训生的发展：药理学、生物化学、 药物化学和制药科学。新的、基于能力的 PSTP 课程， 包括真实世界药物发现的体验式项目，旨在为学员提供强大的 对药理学科学的基本了解，提供严格执行培训 和可重复的研究，并提供职业发展、团队合作和领导力培训，所有这些都在 训练有素且敬业的教师导师的指导。广泛而成功的校友基础提供了 职业指导、网络和未来的就业机会。 PSTP导师鼓励学员思考 广泛关注人类疾病的研究问题，同时将论文研究重点放在一个关键的、未满足的差距上 使用严格的实验设计和方法来获得知识。这个重新设计的强大的、跨学科的、然而 个性化的药理科学培训将为学员带来明显的优势，因为他们将 能够快速就业，并有能力为 NIH 发现新药的使命做出贡献。这 开发新型有效的治疗药物是一项关键的、持续的全球需求，需要严格的 训练有素、富有创新精神的团队成员能够解决医疗保健领域的关键问题。至关重要的是，美国必须继续 培养来自不同背景、接受过药理学科学广泛培训的博士级科学家 了解基础科学和转化医学的实验疗法。密歇根大学首映 全球范围内从事生物医学科学研究和研究生培训的机构。虽然 密歇根大学在与该培训计划相关的部门设有单独的研究生课程，PSTP 是 密歇根大学唯一一个利用教师、校友、密歇根药物发现研究所专业知识的项目， 以及这些单位的学生对促进跨学科教育、合作研究的热情， 职业发展，以及基于团队的目标发现和转化方法 实验疗法的发展。

项目成果

PKC inhibition decreases amphetamine-maintained responding under a progressive-ratio schedule of reinforcement.

PKC 抑制可降低安非他明在渐进比例强化方案下维持的反应。

• 发表时间: 2021-12
• 影响因子: 2.3
• 作者: Altshuler, Rachel D;Mac, Ryan C;Gnegy, Margaret E;Jutkiewicz, Emily M
• 通讯作者: Jutkiewicz, Emily M

Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space.

使用泛化到新突变空间的机器学习模型来共同优化治疗性抗体亲和力和特异性。

• 发表时间: 2022-07-01
• 影响因子: 16.6
• 作者: Makowski, Emily K;Kinnunen, Patrick C;Huang, Jie;Wu, Lina;Smith, Matthew D;Wang, Tiexin;Desai, Alec A;Streu, Craig N;Zhang, Yulei;Zupancic, Jennifer M;Schardt, John S;Linderman, Jennifer J;Tessier, Peter M
• 通讯作者: Tessier, Peter M

Improving antibody drug development using bionanotechnology.

利用生物纳米技术改进抗体药物的开发。

• 发表时间: 2022-04
• 影响因子: 7.7
• 作者: Makowski, Emily K;Schardt, John S;Tessier, Peter M
• 通讯作者: Tessier, Peter M

The ERG1 K+ Channel and Its Role in Neuronal Health and Disease.

ERG1 K 通道及其在神经元健康和疾病中的作用。

• 发表时间: 2022
• 作者: Sanchez;Jimenez;Auerbach, David S;Jones, David K
• 通讯作者: Jones, David K

Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape.

对所关注的 SARS-CoV-2 变体的突变分析揭示了受体亲和力和抗体逃逸之间的关键权衡。

• 发表时间: 2022-05
• 影响因子: 4.3
• 作者: Makowski, Emily K;Schardt, John S;Smith, Matthew D;Tessier, Peter M
• 通讯作者: Tessier, Peter M